NCT02923102

Brief Summary

The aim of the study is to investigate a pre and post workout supplementation (15 days) with Recoverben® , a Aloysia citriodora extract on recovery after exhaustive exercise. Effects will be investigated with 400mg Recoverben® and compared to placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for not_applicable healthy-volunteers

Timeline
Completed

Started Oct 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 28, 2016

Completed
3 days until next milestone

Study Start

First participant enrolled

October 1, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 4, 2016

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2017

Completed
Last Updated

November 6, 2017

Status Verified

November 1, 2017

Enrollment Period

4 months

First QC Date

September 28, 2016

Last Update Submit

November 1, 2017

Conditions

Keywords

RecoveryMuscle sorenessLemon Verbena

Outcome Measures

Primary Outcomes (1)

  • Change of muscle soreness (VAS) over time

    In the current study, pain following eccentric exercise will be assessed by using a 100 mm visual analogue scale after the subjects performing a standardized movement.

    Chance over time after 10 days of supplementation (pre stress test and 3h, 24h, 48 h, 96h after stress test)

Secondary Outcomes (7)

  • Monitoring of related adverse events

    During study execution over 15 days

  • Change of maximal concentric strength/ maximal voluntary contraction (MVC) over time

    Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)

  • Change of pressure pain (Algometry) over time

    Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)

  • Change of retrospective pain (Likert scale) over time

    Chance over time after 10 days of supplementation (pre stress test and 24h, 48h, 96h after stress test)

  • Change of creatine kinase over time

    Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)

  • +2 more secondary outcomes

Study Arms (2)

Aloysia citriodora extract

ACTIVE COMPARATOR

Dietary Supplement: Aloysia citriodora extract

Dietary Supplement: Aloysia citriodora extract

Placebo Formulation

PLACEBO COMPARATOR

Dietary Supplement: Maltodextrin (no active ingredient)

Dietary Supplement: Maltodextrin

Interventions

Aloysia citriodora extractDIETARY_SUPPLEMENT

2 capsules with 200mg - daily dosage 400mg

Also known as: Recoverben®
Aloysia citriodora extract
MaltodextrinDIETARY_SUPPLEMENT

2 capsules with 200mg - daily dosage 400mg

Also known as: Placebo
Placebo Formulation

Eligibility Criteria

Age22 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
  • Health volunteers: Subject is in good physical and mental health as established by medical his-tory, physical examination, electrocardiogram, vital signs, results of biochemistry and haematology
  • Men and women
  • Age ≥ 22 and ≤ 50 years
  • BMI: 19-30 kg/m2
  • Physically active 1-3 times per week
  • Nonsmoker
  • Able and willing to follow the study protocol procedures

You may not qualify if:

  • Relevant history, presence of any medical disorder or chronic intake of medication/dietary supplements (e.g. polyphenols, anti-inflammatory or anti-oxidative drugs or supplements, antihyper-tensive drugs) potentially interfering with this study at screening.
  • For this study clinically relevant abnormal laboratory, vital signs or physical findings at screening
  • Diabetes or serious cardiovascular diseases
  • Change of dietary habits within the 2 weeks prior to screening (for instance start of a diet high in vegetables and fruits (≥ 5 portions per day))
  • Diet high in vegetables and fruits ≥ 5 portions per day
  • Participants anticipating a change in their lifestyle or physical activity levels during the study.
  • Subjects not willing to abstain from intake of analgesic medication (e.g. Aspirin) 24 hours prior to visit 2 until visit 5.
  • Subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to co-operate during the study.
  • Known hypersensitivity to the study preparation or to single ingredients
  • Pregnant subject or subject planning to become pregnant during the study; breast-
  • Known HIV-infection
  • Known acute or chronic hepatitis B and C infection
  • Blood donation within 4 weeks prior to visit 1 or during the study.
  • Subject involved in any clinical or food study within the preceding month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Biotesys GmbH

Esslingen am Neckar, 73728, Germany

Location

Related Publications (1)

  • Buchwald-Werner S, Naka I, Wilhelm M, Schutz E, Schoen C, Reule C. Effects of lemon verbena extract (Recoverben(R)) supplementation on muscle strength and recovery after exhaustive exercise: a randomized, placebo-controlled trial. J Int Soc Sports Nutr. 2018 Jan 23;15:5. doi: 10.1186/s12970-018-0208-0. eCollection 2018.

MeSH Terms

Conditions

Myalgia

Interventions

maltodextrin

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System DiseasesMusculoskeletal PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Claudia Reule, Dr.

    BioTeSys GmbH

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 28, 2016

First Posted

October 4, 2016

Study Start

October 1, 2016

Primary Completion

January 15, 2017

Study Completion

March 15, 2017

Last Updated

November 6, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share

Locations